Exercise, HRV, and Cancer’s Hidden Autonomic Damage

Cancer treatment can damage the heart's control system before it damages the heart muscle

Cancer therapy can lower heart-rate variability (HRV), tilt the nervous system toward sympathetic "fight-or-flight" activity, and suppress vagal activity—the parasympathetic signals that help regulate heart rate. That damage may appear even when an echocardiogram still shows preserved pumping function. Exercise appears to improve some HRV measures, especially in breast cancer research, but the case for formal cardiac rehabilitation is much less settled than its endorsements imply.

A 2021 systematic review and meta-analysis by Lavín-Pérez et al. reported autonomic dysfunction in roughly 80% of patients receiving chemotherapy or radiotherapy. The review evaluated common HRV measures, including SDNN, RMSSD, low-frequency power, high-frequency power, LF/HF ratio, and total power, across aerobic, resistance, combined exercise, yoga, and Tai Chi interventions. Lower SDNN and RMSSD generally indicate poorer autonomic regulation, although HRV is sensitive to how and when researchers measure it.

This matters because anthracyclines such as doxorubicin and epirubicin can disrupt vagal tone independently of a detectable decline in cardiac contractility. In other words, a normal-looking ejection fraction does not rule out altered autonomic control. The proposed biology is plausible: cancer treatment and its physiologic stress can activate the sympathetic nervous system, hypothalamic-pituitary-adrenal axis, and renin-angiotensin-aldosterone system while increasing oxidative stress and inflammation. Those pathways can all suppress parasympathetic regulation. Plausibility, however, does not tell us which workout, dose, or schedule repairs the problem.

Exercise has a signal. The size of the benefit remains unclear.

The 2021 review concluded that exercise may reduce the decline in autonomic function in people with cancer and survivors, but it also described results as controversial across interventions. That wording deserves attention. Studies used different HRV indices, recording positions, recording durations, and analysis software. A change in RMSSD after a five-minute seated recording cannot automatically be pooled with a change in SDNN from a different protocol. The available report also does not provide extractable effect estimates and confidence intervals for the central HRV outcomes, so readers cannot responsibly assign a numerical magnitude to the average benefit.

Still, controlled studies give the idea more than a mechanistic sales pitch. An 18-week randomized trial of integrated yoga in breast cancer patients receiving adjuvant anthracycline chemotherapy found improved cardiac autonomic function, including high-frequency HRV, a parasympathetic index. Its timing is important: the intervention occurred during active treatment, rather than only after treatment ended. The trial supports the possibility that exercise-like behavioral interventions can affect autonomic measures while chemotherapy is underway.

It does not establish durable autonomic recovery. HRV changes during cyclical chemotherapy could partly reflect adaptation to treatment timing rather than a lasting restoration of autonomic function. The study does not report whether its HRV improvements persisted into long-term survivorship.

A 2024 controlled study of an online home-based exercise program also reported improved autonomic dysfunction metrics in breast cancer survivors. That result makes remote delivery plausible, which is useful for people juggling treatment, fatigue, travel, and ordinary life. It does not prove that an app-based program outperforms an equivalent amount of self-directed exercise, nor does it establish fewer cardiovascular events.

A 2025 study of individualized high-intensity online concurrent exercise used real-time autonomic modulation to guide exercise in breast cancer survivors and assessed mental health and quality of life. It shows that HRV-guided delivery is operationally feasible. Its reported outcomes do not establish that this approach produces superior HRV recovery or prevents cardiovascular disease.

Recovery after a workout may be slower than standard training plans assume

The usual progressive-overload template comes from populations that may not have treatment-related autonomic impairment. A 2023 observational study followed only 16 breast cancer survivors after individual exercise sessions and found slow, highly variable, and potentially incomplete day-to-day HRV recovery. The study cannot identify a universal recovery interval or tell whether the variation reflects biology, measurement noise, or both. Its sample is far too small for that.

But it raises a sensible clinical question: should a survivor with impaired autonomic reserve train on the same schedule as a healthy adult? The evidence does not support a universal answer. HRV tracking may help some people and clinicians notice unusual recovery patterns, but daily HRV is not a validated traffic light that can independently prescribe exercise. It is one piece of context alongside symptoms, treatment status, blood counts when relevant, sleep, medications, cardiac history, and clinician guidance.

Autonomic dysfunction extends beyond breast cancer. Exercise evidence does not.

Breast cancer dominates this literature, partly because anthracycline exposure has made cardiotoxicity a major concern in that population. Yet a 2021 descriptive study in lymphoma survivors documented persistent autonomic imbalance after hematologic cancer treatment. That finding argues against treating autonomic dysfunction as a breast-cancer-only issue.

It does not license a simple transfer of breast cancer exercise protocols to lymphoma, lung, colorectal, or other cancer populations. Treatment regimens differ. So do surgical burdens, pulmonary limitations, endocrine therapies, neuropathy, anemia, metastatic disease, and baseline fitness. A 2025 randomized trial of digital cardio-oncology rehabilitation in lung cancer survivors shows that digital rehabilitation can be tested outside breast cancer, but the available findings do not establish HRV improvement or reduced cardiovascular mortality.

Why cardiac rehabilitation has an evidence problem

The uncomfortable part is not that exercise lacks promise. It is that the clinical infrastructure built around that promise has moved faster than its trials. The American Heart Association and American Cancer Society endorse multimodal cardiac rehabilitation for cancer survivors. Yet a systematic review and meta-analysis by Fakhraei et al. judged the evidence supporting cardiac rehabilitation in cancer survivors scant.

The review assessed risk of bias and reporting quality with ROB 2.0, ROBINS-I, TIDieR, CONSORT-Harms, and TESTEX. Most studies were single-arm and nonrandomized, many had high attrition, and intervention and harms reporting was often inadequate. Those weaknesses matter because people who finish an exercise program may differ from people who leave it: they may begin healthier, tolerate fatigue better, have more support, or face fewer treatment complications. Without appropriate comparison groups, randomization, and missing-data methods, better fitness, HRV, or quality-of-life scores cannot be cleanly attributed to rehabilitation.

The outcomes also remain surrogates. HRV and VO2peak can be clinically meaningful markers, but the reviewed literature does not show that exercise-driven improvements in either measure reduce cardiovascular mortality or hard cardiovascular events in cancer survivors. A biomarker improvement is encouraging; it is not the same thing as an outcome trial.

Even remote rehabilitation remains early-stage in places. The REMOTE-COR-B publication is a protocol for a single-arm feasibility trial in breast cancer patients, not evidence of efficacy. Feasibility is useful. It answers whether a program can be delivered; it does not answer whether it changes long-term health.

What a careful person can do with this evidence

For breast cancer patients receiving anthracycline-based chemotherapy, structured aerobic exercise and yoga have directional support for improving autonomic measures during or after treatment. Starting movement during treatment may be reasonable when the oncology team considers it safe; waiting until survivorship is not the only evidence-based option.

The details require humility. No study base here identifies an optimal HRV-restoring dose, intensity, or modality. There is no proof that formal cardiac rehabilitation is superior to comparable self-directed exercise. And there is no long-term outcome evidence showing that a higher HRV reading after training prevents cardiovascular death in cancer survivors.

Exercise is a reasonable tool for countering treatment-related autonomic dysfunction, especially in breast cancer research. It is not yet a validated recipe for reversing cardiotoxicity or a substitute for cardio-oncology care.

The study that would change this picture would randomize large, treatment-stratified cancer populations to clearly described programs, standardize HRV measurement, track harms and adherence, and follow cardiovascular events for years. Until then, the honest position is neither hype nor dismissal: exercise has a credible physiological signal, while the claims made for rehabilitation should stay smaller than the evidence.